Unilife Corporation Fund Company Profile

Description

Unilife Corporation designs, manufactures, and supplies injectable drug delivery systems in the United States and internationally. The company offers Unifill, a pre-filled syringe with integrated, automatic, and user-controlled retraction; Unifill Finesse, an integrated, automatic, and user-controlled retraction with standard plunger seal and plunger rod; Unifill Select, which allows an end-user to select and attach a needle at the time of injection; Unifill Nexus that is equipped with an integrated luer adapter to provide connectivity with needleless luer access devices; and Unifill Allure, that allows the end-user to select and attach a needle with a universal luer connection at the time of injection with automatic, user-controlled needle retraction. It also provides ReadyToGo, a portfolio of wearable injectors for pre-filled, disposable devices that can be worn by a patient over periods; Imperium platform, a prefilled, disposable, and multi-day wearable insulin pump; and LISA smart reusable and RITA disposable auto-injectors. In addition, the company offers drug reconstitution delivery systems, such as AutoMix Presto, an automatic reconstitution for single-step mixing and injection; EZMix Genesis, a ventless one-step reconstitution and automatic user-controlled retraction; EZMix Engage to attach and retract a needle; and EZMix Prodigy, a single-barrel reconstitution system with a pre-fillable syringe. Further, it provides ocular delivery systems comprising Ocu-ject for the delivery of microliter sized doses to the eye; Ocu-mix, a dual-chamber syringe platform to reconstitute or mix, and deliver various therapies into the eye with a single injection; and Depot-ject, which places a drug depot into the eye. Additionally, the company offers Micro-ject to optimize the delivery of therapies with microliter doses. It serves pharmaceutical and biotechnology companies. The company was founded in 2002 and is headquartered in York, Pennsylvania.